Clinical Trial

Vonafexor in Patients With Impaired Renal Function and Suspected MASH (Metabolic Dysfunction-associated Steatohepatitis)

Study acronym: MASH
Terminated Phase 2
View on ClinicalTrials.gov →
Why the trial stopped
Pilot cohort (n=10) yielded useful insights but data remains exploratory due to limited sample size. Study stopped due to strategic reprioritization.
Summary
This study is designed to establish the effect of 2 doses of vonafexor on the kidney. This will be investigated in subjects with mild or moderate reduced estimated glomerular filtration rate (eGFR) and suspected MASH. In addition, the non-invasive multiparametric magnetic resonance imaging assessment of functional and structural changes in the kidney and in the liver will be investigated.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-15; most recent amendment 2026-04-20.
Status change: Recruiting → Terminated 2026-04-20
Status change: Not Yet Recruiting → Recruiting 2025-07-01
Trial Details
NCT Number NCT06939816
Lead Sponsor Enyo Pharma
Conditions Chronic Kidney Disease Stage 2, Chronic Kidney Disease Stage 3, Metabolic Dysfunction-Associated Steatohepatitis
Enrollment 10 participants
Start Date 2025-07-01
Primary Completion 2025-12-22 (estimated)
Study Completion 2026-03-13 (estimated)
Updated on ClinicalTrials.gov 2026-04-23